Accuracy of Peak Cough Flow Measurements Using a Mechanical Insufflator-exsufflator (MIEPCF)

Accuracy of Peak Cough Flow Measurements Using a Mechanical Insufflator-exsufflator in Patients With Neuromuscular Disease: A Single Centre Prospective Observational Study

The primary aim of this study is to evaluate the agreement of MIE devices measurement of MIE assisted peak cough flow (PCF) compared with a pneumotachographs during usual MIE care. This will be the first study to do this through range of MIE pressures and include patients who are receiving MIE via a tracheostomy. It will also aim to evaluate the intra-subject repeatability of measures for patients who receive more than one MIE cycle as part of their usual care. It will be the first to measure MIE assisted PCF contemporaneously during intervention using the gold standard pneumotachograph. This will inform treatment effect size and the efficacy of usual practice MIE in augmenting PCF measurements above critical cut off values for effective cough and secretion clearance.

Finally the study will also aim to understand how patients perceive the impact of MIE in clearing secretions from their chest by asking them to rate presence of chest secretions pre and post intervention using a visual analogue scale (VAS)

Study Overview

• Status: Completed
• Conditions: Neuromuscular Diseases
• Intervention / Treatment: Device: Mechanical Insufflator-Exsufflator

Detailed Description

Patients with a neuromuscular disease (NMD) lose strength in their breathing muscles which leads to an inability to generate an effective cough. Peak Cough Flow (PCF) is a simple objective measure of cough and is the recommended measure in patients with NMD. Critical peak cough flow values are used to evaluate cough, these include PCF less than 160 L/min to indicate an ineffective cough, PCF between 161- 270 to indicate an impaired cough and PCF greater than 270 L/min to indicate an effective cough. Mechanical insufflator- exsufflator (MIE) devices more commonly known as 'cough assist' devices have an inbuilt measure of PCF however they aren't currently recommended for use to due to limited information available regarding their accuracy. This will be a single centre prospective observational study. Once patients have consented to participate in the study, they will be visited once on the unit during their admission by the researcher with the visit lasting approximately an hour.

During the visit they will receive their usual care MIE with a pneumotachograph fitted into the circuit. The primary outcome is the agreement of MIE assisted PCF measures between the MIE device and pneumotachograph. Before and after the intervention the patient will be asked to rate the presence of mucous in their lungs using a visual analogue scale.

The following data will be recorded

• Neuromuscular diagnosis
• Age, height, weight,
• Comorbidities
• Hospital length of stay (Days)
• Ventilation dependency(hours/Day)
• Bronchodilator and/or mucolytic medications
• Vital observations (heart rate, blood pressure, oxygen saturations)
• Method of MIE delivery (mask or tracheostomy)
• Tracheostomy size, type and brand
• Bulbar function if available (Laryngoscope)
• Spirometry - Forced Expired Volume in 1 second (FEV1), Forced Vital Capacity (FVC), (from clinical notes)
• Voluntary PCF (collected from patient by researcher)
• MIE Mode (collected from device by researcher)
• MIE Total number cycle repeats (collected from device by researcher)
• MIE device Inspiratory pressure (collected from device by researcher)
• MIE inspiratory pressure at interface (Pressure transducer)
• MIE inspiratory time (collected from device by researcher)
• MIE peak inspiratory Flow (from device by researcher)
• MIE device expiratory pressure (collected from device by researcher)
• MIE expiratory pressure at interface (Pressure transducer)
• MIE Expiratory time (collected from device by researcher)
• MIE Assisted PCF Pneumotachograph (From patient by researcher)
• MIE Assisted PCF MIE (From patient by researcher)
• Visual Analogue Scale regarding secretion presence pre and post MIE (from patient by researcher)

• Study Type: Observational
• Enrollment (Actual): 10

Contacts and Locations

Study Locations

• United Kingdom
  • London, United Kingdom, SE1 7EH
    • Guy's and St. Thomas NHS Foundation Trust

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

Patient with neuromuscular related respiratory failure and receiving MIE as part of their usual care

Description

Inclusion Criteria:

• Patients with neuromuscular disease-related respiratory failure and are receiving MIE as part of their usual care
• Patients who are clinical stable and documented as such by the supervising clinician
• Patients who are cognitively intact and have the capacity able to provide informed consent

Exclusion Criteria:

• Pregnancy
• Aged <18
• Significant physical or psychiatric co-morbidity that would prevent compliance with trial protocol

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Agreement of Peak Cough Flow between MIE and pneumotachograph.	Peak Cough Flow measure the peak flow of expired air during the exsufflation phase of cough or MIE assisted cough	Data will be collected at the point of recruitment to the study and then be reported within 1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Visual Analogue Scale	Patients will be asked regarding their perceived presence of chest secretions pre and post and post intervention using the visual analogue scale. The scale ranges from 0 to 10 with 10 being the highest perceived score.	Data will be collected at the point of recruitment to the study and then be reported within 1 year
Treatment effect size of PCF during usual MIE care	Will compared baseline voluntary PCF to MIE assisted PCF	Data will be collected at the point of recruitment to the study and then be reported within 1 year
Exploratory analysis of MIE Pressure and PCF	Exploratory analysis of the correlation between MIE Pressure with PCF and cough function will be performed using chi square, correlation and logistic regression as appropriate.	Data will be collected at the point of recruitment to the study and then be reported within 1 year
Exploratory analysis of MIE inspiratory Volume and PCF	Exploratory analysis of the correlation between MIE inspiratory volume with PCF and cough function will be performed using chi square, correlation and logistic regression as appropriate.	Data will be collected at the point of recruitment to the study and then be reported within 1 year
Intra-subject variance of repeated PCF measures	For patient receiving more than one cycle of MIE during their usual care, the repeated PCF measures taken by MIE and Pneumotachograph and variance of measures evaluated	Data will be collected at the point of recruitment to the study and then be reported within 1 year

Collaborators and Investigators

• Sponsor: Guy's and St Thomas' NHS Foundation Trust
• Investigators: Principal Investigator: Leyla Osman, Guy's and St Thomas' NHS Foundation Trust

Study record dates

Study Major Dates

• Study Start (Actual): December 4, 2020
• Primary Completion (Actual): September 1, 2021
• Study Completion (Actual): September 1, 2021

Study Registration Dates

• First Submitted: February 5, 2020
• First Submitted That Met QC Criteria: June 15, 2021
• First Posted (Actual): June 23, 2021

Study Record Updates

• Last Update Posted (Actual): January 26, 2022
• Last Update Submitted That Met QC Criteria: January 11, 2022
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Neuromuscular Diseases
• Other Study ID Numbers: 272851

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No